Aron Flagg, MD
Assistant Professor of Pediatrics (Hematology/Oncology)Cards
About
Research
Publications
Featured Publications
Gimap5-dependent inactivation of GSK3β is required for CD4+ T cell homeostasis and prevention of immune pathology
Patterson AR, Endale M, Lampe K, Aksoylar HI, Flagg A, Woodgett JR, Hildeman D, Jordan MB, Singh H, Kucuk Z, Bleesing J, Hoebe K. Gimap5-dependent inactivation of GSK3β is required for CD4+ T cell homeostasis and prevention of immune pathology. Nature Communications 2018, 9: 430. PMID: 29382851, PMCID: PMC5789891, DOI: 10.1038/s41467-018-02897-7.Peer-Reviewed Original ResearchConceptsCell proliferationGlycogen synthase kinase-3βC-myc inductionT cell proliferationSynthase kinase-3βNuclear importSer389 phosphorylationGSK3 inhibitorsCell homeostasisT cellsFunction mutationsKinase-3βGenetic targetingDNA damageProtein 5Nuclear translocationT cell homeostasisGSK3β activityT cell activationImportant checkpointGSK3βGimap5Pharmacological inhibitionGIMAP5 deficiencyLymphocyte survivalCharacteristics of Bacteremia in Pediatric Oncology Patients Based on Pathogen Classification as Associated with the Gastrointestinal Mucosa or Skin
Flagg A, Worley S, Foster CB. Characteristics of Bacteremia in Pediatric Oncology Patients Based on Pathogen Classification as Associated with the Gastrointestinal Mucosa or Skin. Infection Control And Hospital Epidemiology 2015, 36: 730-733. PMID: 25773335, DOI: 10.1017/ice.2015.48.Peer-Reviewed Original ResearchConceptsGastrointestinal mucosaCharacteristics of bacteremiaEnteric Gram-negativesBlood stream infectionsPediatric oncology patientsAcute myelogenous leukemiaCentral cathetersOncology patientsOral floraMyelogenous leukemiaSkin organismsBacteremiaPatientsMucosaGram-negativesMucositisCatheterLeukemiaInfectionLymphocyte cytosolic protein 1 (L-plastin) I232F mutation impairs granulocytic proliferation and causes neutropenia
Mahat U, Garg B, Yang CY, Mehta H, Hanna R, Rogers HJ, Flagg A, Ivanov AI, Corey SJ. Lymphocyte cytosolic protein 1 (L-plastin) I232F mutation impairs granulocytic proliferation and causes neutropenia. Blood Advances 2022, 6: 2581-2594. PMID: 34991157, PMCID: PMC9043934, DOI: 10.1182/bloodadvances.2021006398.Peer-Reviewed Original ResearchConceptsLymphocyte cytosolic protein 1Impaired cell motilityDiffuse intracellular localizationUnfolded protein responseCytosolic protein 1Level of genesCell cycle arrestActin regulationG2/M phaseNew genesActin cytoskeletonActin dynamicsCell motilityProtein responseSubcellular fractionationMutant formsF-actinIntracellular localizationWhole-exome sequencingCycle arrestHeLa cellsMissense mutationsHeterozygous missense mutationM phaseLCP1Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow SD. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2021, 19: 1277-1303. PMID: 34781268, DOI: 10.6004/jnccn.2021.0053.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHistiocytic neoplasmsNCCN Clinical Practice GuidelinesCommon histiocytic disorderRare hematologic disorderRosai-Dorfman diseaseTreatment of adultsClinical practice guidelinesErdheim-Chester diseaseLangerhans cell histiocytosisNCCN guidelinesSelect patientsSystemic therapyLymph nodesClinical presentationMild diseaseCell histiocytosisHematologic disordersHistiocytic disorderPractice guidelinesOptimal managementPatientsNeoplasmsSoft tissueDiseaseDisordersIncidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant
Dandoy CE, Kim S, Chen M, Ahn KW, Ardura MI, Brown V, Chhabra S, Diaz MA, Dvorak C, Farhadfar N, Flagg A, Ganguly S, Hale GA, Hashmi SK, Hematti P, Martino R, Nishihori T, Nusrat R, Olsson RF, Rotz SJ, Sung AD, Perales MA, Lindemans CA, Komanduri KV, Riches ML. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open 2020, 3: e1918668. PMID: 31913492, PMCID: PMC6991246, DOI: 10.1001/jamanetworkopen.2019.18668.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantMucosal barrier injury laboratoryMBI-LCBIOutcomes of patientsStem cell transplantBloodstream infectionsCumulative incidenceCell transplantRisk factorsDay 100First allogeneic hematopoietic stem cell transplantMarrow Transplant Research databaseHost disease (GVHD) prophylaxisLansky performance statusTransplant-related mortalityOne-year mortalityTranslocation of bacteriaCord blood graftsCause of deathChronic graftConsecutive pediatricHost diseaseMyeloablative conditioningAdult patientsInfectious diseases in pediatric transplantation: Literature review 2006–2007
Flagg A, Danziger‐Isakov L. Infectious diseases in pediatric transplantation: Literature review 2006–2007. Pediatric Transplantation 2008, 12: 729-736. DOI: 10.1111/j.1399-3046.2008.00985.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsExtranodal marginal zone B cell lymphoma: An unexpected complication in children with Sjögren's syndrome
Collado P, Kelada A, Cámara M, Zeft A, Flagg A. Extranodal marginal zone B cell lymphoma: An unexpected complication in children with Sjögren's syndrome. Reumatología Clínica (English Edition) 2018, 14: 227-229. DOI: 10.1016/j.reumae.2017.01.011.Peer-Reviewed Original ResearchExtranodal marginal zone B-cell lymphomaSjögren's syndromeB-cell lymphomaMarginal zone B-cell lymphomaDiagnosis of SSJuvenile Sjögren's syndromeSalivary glandsPrimary Sjögren's syndromeSystemic autoimmune diseaseInfiltration of lymphocytesRisk of malignancyFine-needle aspirationSicca symptomsNonspecific findingsAutoimmune diseasesUnusual complicationRare conditionNeedle aspirationImmunohistochemical stainingUnexpected complicationsSyndromeExocrine glandsComplicationsLymphomaChildrenNovel 2009 H1N1 influenza virus infection requiring extracorporeal membrane oxygenation in a pediatric heart transplant recipient
Flagg A, Danziger-Isakov L, Foster C, Nasman C, Smedira N, Carl J, Kwon C, Davis S, Boyle G. Novel 2009 H1N1 influenza virus infection requiring extracorporeal membrane oxygenation in a pediatric heart transplant recipient. The Journal Of Heart And Lung Transplantation 2009, 29: 582-584. PMID: 20044274, DOI: 10.1016/j.healun.2009.11.600.Peer-Reviewed Case Reports and Technical NotesConceptsExtracorporeal membrane oxygenationH1N1 influenza virusAcute respiratory distress syndromeCardiothoracic transplant recipientsTransplant recipientsInfluenza virusMembrane oxygenationSevere acute respiratory distress syndromeH1N1 influenza virus infectionPediatric heart transplant recipientsHeart transplant recipientsRespiratory distress syndromeInitiation of treatmentInfluenza virus infectionReal-time reverse transcriptase-polymerase chain reactionCongenital heart diseaseReverse transcriptase-polymerase chain reactionIncidence of infectionTranscriptase-polymerase chain reactionPediatric recipientsDistress syndromePediatric patientsLung diseaseHeart diseaseEarly suspicion
2024
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease
Krishnamurti L, Liang J, He Z, Deng Y, Nallagatla V, Hamidi R, Flagg A, Shah N. Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease. Blood Advances 2024, 8: 1908-1919. PMID: 38324722, PMCID: PMC11021890, DOI: 10.1182/bloodadvances.2023010749.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseVaso-occlusive episodesPainful crisesCell transplantationPost-HCTGraft failureBefore HCTEvent-free survivalOverall survivalPain syndromePatient agePatient-centered outcomesAlternative donorsIncreased riskCell diseaseRisk factorsNatural historyPatientsLogistic regressionPainTransplantationSurvivalAgeAGVHD
2023
378 Main Reasons for Performing Hematopoietic Cell Transplantation in Patients with Sickle Cell Disease: Evolution over the Last Three Decades
Flagg A, He Z, Deng Y, Hamidi R, Shah N, Krishnamurti L. 378 Main Reasons for Performing Hematopoietic Cell Transplantation in Patients with Sickle Cell Disease: Evolution over the Last Three Decades. Transplantation And Cellular Therapy 2023, 29: s285-s286. DOI: 10.1016/s2666-6367(23)00447-5.Peer-Reviewed Original Research
Clinical Trials
Current Trials
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease
HIC ID2000032707RoleSub InvestigatorPrimary Completion Date08/01/2025Recruiting ParticipantsA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)
HIC ID2000032969RoleSub InvestigatorPrimary Completion Date07/05/2028Recruiting ParticipantsA Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
HIC ID2000032978RoleSub InvestigatorPrimary Completion Date12/30/2026Recruiting ParticipantsA Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
HIC ID2000028691RoleSub InvestigatorPrimary Completion Date05/01/2027Recruiting ParticipantsA Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
HIC ID2000021396RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting Participants
Clinical Care
Overview
Aron Flagg, MD, is a pediatric hematologist/oncologist and specializes in treating children who need bone marrow or stem cell transplants.
Dr. Flagg’s expertise includes immune deficiency and lymphoblastic leukemia, a common childhood cancer that affects the blood and bone marrow.
Dr. Flagg says he can trace his fascination with medicine back to age 5 when his parents gave him an anatomy coloring book. “I just always had an interest in medicine and ended up in pediatrics because I enjoyed the patients so much,” he says. “Although oncology was not my initial goal, I found I loved the continuity of care. Plus, it’s such a rewarding field. When you have a child who gets a transplant and you see them years later leading a normal life, it’s wonderful.”
During medical school, Dr. Flagg became interested in the infectious and immunological consequences of transplant and decided to pursue fellowship training that combined pediatric hematology/oncology and infectious diseases.
“There are many infectious complications patients can have after transplant, often due to chemotherapy because it affects the immune system,” Dr. Flagg explains. “I’m interested in how we can better prevent those infections and take better care of patients when they do occur.”
The best part of his job, Dr. Flagg says, is working with children and their families. “It’s not just taking care of the patient, but the parents, the siblings, and anyone who is an important part of a child’s life,” he says.
Clinical Specialties
Fact Sheets
Neutropenia
Learn More on Yale MedicineCAR T-Cell Therapy
Learn More on Yale MedicinePediatric Chemotherapy
Learn More on Yale MedicineHyperthermic Intraperitoneal Chemotherapy (HIPEC)
Learn More on Yale Medicine
Board Certifications
Pediatric Hematology-Oncology
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 2017
Pediatric Infectious Disease
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 2013
Pediatrics
- Certification Organization
- AB of Pediatrics
- Latest Certification Date
- 2016
- Original Certification Date
- 2008
Yale Medicine News
News
News
- September 25, 2024
Childhood Cancer Awareness Month Faculty Spotlight On: Aron Flagg, MD
- October 12, 2022
Pediatric Bone Marrow Transplant Reunion
- June 16, 2021
Department of Pediatrics Faculty Awards for the 2020-21 Academic Year